Mersana Therapeutics

$18.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.84 (-4.37%) Today
-$0.18 (-0.98%) As of 1:00 PM UTC after-hours

Why Robinhood?

You can buy or sell MRSN and other stocks, options, and ETFs commission-free!

About MRSN

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in oncology indications. Its product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC) and XMT-1536, which focuses on ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA. The listed name for MRSN is Mersana Therapeutics, Inc. Common Stock.

CEO
Anna Protopapas
Employees
83
Headquarters
Cambridge, Massachusetts
Founded
2001
Market Cap
1.25B
Price-Earnings Ratio
Dividend Yield
Average Volume
867.05K
High Today
$19.69
Low Today
$18.10
Open Price
$19.25
Volume
1.14M
52 Week High
$29.09
52 Week Low
$4.12

MRSN Earnings

-$0.42
-$0.38
-$0.34
-$0.30
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.32 per share
Actual
-$0.42 per share
Join Live Earnings Call

You May Also Like

REFR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure